SCHEMBL21947500

SCHEMBL21947500

COc1ccc(S(=O)(=O)NC2CCOC2)cc1C(=O)Nc1cc(Cl)cc(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.56
TP53 P04637 4/20 0.56
POLB P06746 1/20 0.56
HTR2B P41595 1/20 0.49
LMNA P02545 3/20 0.46
NPC1 O15118 2/20 0.46
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPK1 P28482 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
GSTO1 P78417 1/20 0.43
PDE4A P27815 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21569207 1.00 MAPT (0.56) MAPTTP53POLBHTR2BLMNA
SCHEMBL21545565 0.94 MAPT (0.55) MAPTTP53POLBHTR2BLMNA
SCHEMBL21545566 0.94 MAPT (0.55) MAPTTP53POLBHTR2BLMNA
SCHEMBL21569361 0.93 TP53 (0.56) MAPTTP53POLBHTR2BLMNA
SCHEMBL21947439 0.93 TP53 (0.56) MAPTTP53POLBHTR2BLMNA
SCHEMBL21569520 0.92 HTR2B (0.54) MAPTTP53POLBHTR2BLMNA
SCHEMBL21947448 0.92 HTR2B (0.54) MAPTTP53POLBHTR2BLMNA
SCHEMBL21545505 0.92 TP53 (0.48) MAPTTP53POLBHTR2BLMNA
SCHEMBL21545502 0.92 TP53 (0.48) MAPTTP53POLBHTR2BLMNA
SCHEMBL21947554 0.89 GSTO1 (0.51) MAPTTP53POLBHTR2BLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654837-B2 Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis JANSSEN PHARMACEUTICA NV (BE) 2020-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10654837-B2 Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis HTR2B, HTR3B, HTR1A MAPT 4615/4885TP53 3645/4885POLB 4474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.